Analyzing Evelo Biosciences (NASDAQ:EVLO) & Antibe Therapeutics (OTCMKTS:ATBPD)
Antibe Announces Appointment of Receiver
Antibe Provides Update on CCAA Proceedings
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
Antibe Reports Q3 2024 Interim Financial and Operating Results
Antibe Extends Early Warrant Exercise Incentive Program
Antibe Announces Early Warrant Exercise Incentive Program
Antibe Therapeutics Announces Amendment to Warrant Terms
Antibe Reports Q2 2024 Interim Financial and Operating Results
Antibe Reports PK Results of First Clinical Study of Otenaproxesul's New Formulation
Antibe Completes First Clinical Study of Otenaproxesul's New Formulation
Antibe Initiates First Clinical Study of Otenaproxesul's New Formulation
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
Antibe Announces Results of 2023 Annual Meeting
Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite
Antibe Reports Q1 2024 Interim Financial and Operating Results
Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022